Literature DB >> 22310230

Methoxychalcone inhibitors of androgen receptor translocation and function.

Yeong Sang Kim1, Vineet Kumar, Sunmin Lee, Aki Iwai, Len Neckers, Sanjay V Malhotra, Jane B Trepel.   

Abstract

Androgen receptor activity drives incurable castrate-resistant prostate cancer. All approved antiandrogens inhibit androgen receptor-driven transcription, and in addition the second-generation antiandrogen MDV3100 inhibits ligand-activated androgen receptor nuclear translocation, via an unknown mechanism. Here, we report methoxychalcones that lock the heat shock protein 90-androgen receptor complex in the cytoplasm in an androgen-non-responsive state, thus demonstrating a novel chemical scaffold for antiandrogen development and a unique mechanism of antiandrogen activity. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310230      PMCID: PMC3308679          DOI: 10.1016/j.bmcl.2011.12.141

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  25 in total

1.  New therapies for castration-resistant prostate cancer.

Authors:  Dan L Longo
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

Review 2.  Developments in nonsteroidal antiandrogens targeting the androgen receptor.

Authors:  Bo Liu; Lei Su; Jingkun Geng; Junjie Liu; Guisen Zhao
Journal:  ChemMedChem       Date:  2010-10-04       Impact factor: 3.466

Review 3.  Androgen regulation of gene expression.

Authors:  Kristin R Lamont; Donald J Tindall
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

Review 4.  Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

Authors:  Michael L Mohler; Casey E Bohl; Amanda Jones; Christopher C Coss; Ramesh Narayanan; Yali He; Dong Jin Hwang; James T Dalton; Duane D Miller
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

Review 5.  Innovations in the systemic therapy of prostate cancer.

Authors:  Dale R Shepard; Derek Raghavan
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

Review 6.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

Authors:  Karen E Knudsen; Trevor M Penning
Journal:  Trends Endocrinol Metab       Date:  2010-02-06       Impact factor: 12.015

Review 7.  Blockade of testicular and adrenal androgens in prostate cancer treatment.

Authors:  Fernand Labrie
Journal:  Nat Rev Urol       Date:  2011-01-18       Impact factor: 14.432

8.  Steroid hormone receptors in prostate cancer: a hard habit to break?

Authors:  Gerhardt Attard; Colin S Cooper; Johann S de Bono
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 9.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

Review 10.  Trends in utilization of the pharmacological potential of chalcones.

Authors:  Daniela Ilieva Batovska; Iva Todorova Todorova
Journal:  Curr Clin Pharmacol       Date:  2010-02
View more
  8 in total

1.  1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

Authors:  Claudia Ferroni; Antonella Pepe; Yeong Sang Kim; Sunmin Lee; Andrea Guerrini; Marco Daniele Parenti; Anna Tesei; Alice Zamagni; Michela Cortesi; Nadia Zaffaroni; Michelandrea De Cesare; Giovanni Luca Beretta; Jane B Trepel; Sanjay V Malhotra; Greta Varchi
Journal:  J Med Chem       Date:  2017-03-20       Impact factor: 7.446

2.  Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.

Authors:  Antonella Pepe; Michael Pamment; Yeong Sang Kim; Sunmin Lee; Min-Jung Lee; Kristin Beebe; Anton Filikov; Len Neckers; Jane B Trepel; Sanjay V Malhotra
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

Review 3.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

Review 4.  Advances in androgen receptor targeted therapy for prostate cancer.

Authors:  Alia Ahmed; Shadan Ali; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

5.  Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer.

Authors:  Catherine C Going; Dhanir Tailor; Vineet Kumar; Alisha M Birk; Mallesh Pandrala; Meghan A Rice; Tanya Stoyanova; Sanjay Malhotra; Sharon J Pitteri
Journal:  J Proteome Res       Date:  2018-09-20       Impact factor: 4.466

6.  Meeting Proceedings ICBS2016-Translating the Power of Chemical Biology to Clinical Advances.

Authors:  Yugo Kuriki; Toru Komatsu; Peter D Ycas; Sara K Coulup; Erick J Carlson; William C K Pomerantz
Journal:  ACS Chem Biol       Date:  2017-03-17       Impact factor: 5.100

Review 7.  Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope.

Authors:  Sirin Saranyutanon; Sanjeev Kumar Srivastava; Sachin Pai; Seema Singh; Ajay Pratap Singh
Journal:  Cancers (Basel)       Date:  2019-12-23       Impact factor: 6.639

8.  SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.

Authors:  Meghan A Rice; Vineet Kumar; Dhanir Tailor; Fernando Jose Garcia-Marques; En-Chi Hsu; Shiqin Liu; Abel Bermudez; Vijayalakshmi Kanchustambham; Vishnu Shankar; Zintis Inde; Busola Ruth Alabi; Arvind Muruganantham; Michelle Shen; Mallesh Pandrala; Rosalie Nolley; Merve Aslan; Ali Ghoochani; Arushi Agarwal; Mark Buckup; Manoj Kumar; Catherine C Going; Donna M Peehl; Scott J Dixon; Richard N Zare; James D Brooks; Sharon J Pitteri; Sanjay V Malhotra; Tanya Stoyanova
Journal:  Cell Rep Med       Date:  2022-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.